Red Queen Bio
PrivateLast Round
Seed
Nov 14, 2025
Est. Valuation
$22.5M
Total Funding Raised
$15M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Red Queen Bio operates in Healthcare & Life Sciences and is based in Boston, Massachusetts. Its latest recorded funding round was a Seed round in November 2025.
Red Queen Bio is a biotechnology company that develops biosecurity technology to defend against emerging biological threats enabled by artificial intelligence.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting, Government Contracts
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Red Queen Bio Comparables
Compare Red Queen Bio with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| ResistanceBio | 83% | |
| Valthos | 76% | |
| Paratus Sciences | 74% |
For institutional investors. Book with your work email.
Red Queen Bio Funding Rounds
Historical fundraising activity
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Red Queen Bio Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Cerberus Ventures | Seed |
| Halcyon Ventures | Seed |
| LongeVC | Seed |
| Fifty Years | Seed |
Market signals
Structured signals derived from secondary market and firmographic data.
- Sep 18, 2026
Grew 23% QoQ, from 13 to 16 employees.
- Aug 21, 2026
Monthly visitors increased 54% MoM.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- is_developingSep 29, 2026
Red Queen, backed by OpenAI, is developing AI-driven antibody drugs to preemptively combat potential pathogens created by malicious AI systems.
- is_developingSep 28, 2026
On Sep 28th '26, Red Queen is developing AI-powered antibody drugs to protect against a wide range of viruses, with initial antibodies targeting bird flu and other influenza viruses and first clinical trials planned for 2027.
For institutional investors. Book with your work email.
Red Queen Bio Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Red Queen Bio's valuation, stock price, and market status.
Is Red Queen Bio a public or private company?
Red Queen Bio is a private company.
What is the current stock price of Red Queen Bio?
Red Queen Bio is a private company, so its shares have no public market price. Caplight tracks Red Queen Bio's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Red Queen Bio worth (valuation)?
Red Queen Bio's valuation is estimated at $22.5M based on funding round data.
Can I buy Red Queen Bio stock?
Red Queen Bio shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Red Queen Bio's last funding round?
Red Queen Bio's most recent funding round was Seed on November 14, 2025.
Who are the main investors in Red Queen Bio?
Key investors in Red Queen Bio include Cerberus Ventures, Halcyon Ventures, LongeVC, Fifty Years.
Will Red Queen Bio IPO soon?
No public IPO plans have been announced for Red Queen Bio.
How can I track Red Queen Bio secondary market activity?
Caplight tracks bids, offers, and trades in Red Queen Bio's shares on secondary markets.